Cytokinetics vs Viridian Therapeutics, Inc.\DE
CYTK and VRDN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CYTK and VRDN compare
Viridian Therapeutics, Inc.\DE is the larger company, worth 357 times as much as Cytokinetics ($2.8B against $7.8M).
Viridian Therapeutics, Inc.\DE grew revenue faster over the last twelve months (23220% versus −21.1% for Cytokinetics).
Viridian Therapeutics, Inc.\DE keeps more of each dollar of sales as profit, with a net margin of −544% compared with −1321% at Cytokinetics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CYTK | VRDN |
|---|---|---|
| Size and price | ||
| Market cap | $7.8M | $2.8B |
| Share price | $62.99 | $24.67 |
| Change, 1 year | 1.6% | 7.2% |
| Change, 5 years | 53.3% | 29.9% |
| Beta (5Y) | 0.82 | 0.84 |
| Employees | 673 | 252 |
| StockData Score | ||
| Total score | 4 | 4 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.1× (better) | 39.3× |
| P/B | – | 4.2× |
| FCF yield | −7408% | −12.0% (better) |
| Fair value | – | $8.68 |
| Margin of safety | – | −184% |
| Growth | ||
| Revenue growth (TTM) | −21.1% | 23220% (better) |
| Revenue growth, 5Y average | 9.5% | 132% (better) |
| Profitability | ||
| Operating margin | −1046% | −570% (better) |
| Net margin | −1321% | −544% (better) |
| FCF margin | −858% | −471% (better) |
| Return on equity | – | −65.7% |
| Financial health | ||
| Interest coverage | – | −26.0× |
| Current ratio | 6.66 | 16.95 (better) |
| Altman Z-score | −3.37 | 1.81 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −2.1% |
| Shareholder yield | 0.00% (better) | −2.1% |
| Ownership | ||
| Held by institutions | 115% | 120% |
| Held by insiders | 0.68% | 21.8% |
| Insider net buying, 12 months | −$50.6M | $19.6M (better) |
| Short interest, % of float | 14.0% | 20.3% |
Go deeper
- CYTK stock overview
- CYTK income statement
- CYTK valuation and score
- VRDN stock overview
- VRDN income statement
- VRDN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.